Amicus Therapeutics (FOLD) 10-Q7 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Oct. 25, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-33497
Entity Registrant Name	Amicus Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	71-0869350
Entity Address, Address Line One	3675 Market Street,
Entity Address, City or Town	Philadelphia,
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19104
City Area Code	(215)
Local Phone Number	921-7600
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	FOLD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		280,945,247
Entity Central Index Key	0001178879
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 277,592	$ 245,197
Investments in marketable securities	77,108	237,299
Accounts receivable	52,303	52,672
Inventories	13,272	26,818
Prepaid expenses and other current assets	38,264	34,848
Total current assets	458,539	596,834
Operating lease right-of-use assets, net	29,871	20,586
Property and equipment, less accumulated depreciation of $23,337 and $19,882 at September 30, 2022 and December 31, 2021, respectively	32,449	42,496
In-process research & development	23,000	23,000
Goodwill	197,797	197,797
Other non-current assets	17,872	24,427
Total Assets	759,528	905,140
Current liabilities:
Accounts payable	12,046	21,513
Accrued expenses and other current liabilities	125,235	98,153
Contingent consideration payable	19,833	18,900
Operating lease liabilities	7,536	7,409
Total current liabilities	164,650	145,975
Long-term debt	391,319	389,357
Operating lease liabilities	52,012	43,363
Deferred reimbursements	5,906	5,906
Deferred income taxes	4,930	4,930
Other non-current liabilities	8,146	8,240
Total liabilities	626,963	597,771
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 280,887,136 and 278,912,800 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	2,813	2,808
Additional paid-in capital	2,645,372	2,595,419
Accumulated other comprehensive (loss) gain:
Foreign currency translation adjustment	(38,724)	5,251
Unrealized loss on available-for-sale securities	(354)	(270)
Warrants	83	83
Accumulated deficit	(2,476,625)	(2,295,922)
Total stockholders’ equity	132,565	307,369
Total Liabilities and Stockholders’ Equity	$ 759,528	$ 905,140

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) $ in Thousands	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 $ / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 $ / shares
Statement of Financial Position [Abstract]
Accumulated depreciation of property and equipment \| $	$ 23,337		$ 19,882
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01		$ 0.01
Common stock, shares authorized (in shares)	500,000,000		500,000,000
Common stock, shares issued (in shares)	280,887,136		278,912,800
Common stock, shares outstanding (in shares)	280,887,136		278,912,800

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 $ / shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2021 $ / shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 $ / shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2021 $ / shares
Revenue:
Net product sales	$ 81,691		$ 79,545		$ 241,137		$ 223,360
Cost of goods sold	13,436		11,696		29,215		26,615
Gross profit	68,255		67,849		211,922		196,745
Operating expenses:
Research and development	52,970		59,333		212,806		186,453
Selling, general, and administrative	47,272		46,107		158,767		135,109
Changes in fair value of contingent consideration payable	567		3,288		(506)		4,780
Loss on impairment of assets	0		0		6,616		0
Depreciation and amortization	1,286		1,520		4,031		4,691
Total operating expenses	102,095		110,248		381,714		331,033
Loss from operations	(33,840)		(42,399)		(169,792)		(134,288)
Other income (expense):
Interest income	563		108		1,052		323
Interest expense	(9,620)		(8,165)		(26,024)		(24,307)
Loss on extinguishment of debt	0		(257)		0		(257)
Other income (expense)	13,634		237		22,804		(2,729)
Loss before income tax	(29,263)		(50,476)		(171,960)		(161,258)
Income tax (expense) benefit	(4,023)		182		(8,743)		(5,925)
Net loss attributable to common stockholders	$ (33,286)		$ (50,294)		$ (180,703)		$ (167,183)
Net loss attributable to common stockholders per common share - basic (in dollars per share) \| $ / shares		$ (0.12)		$ (0.19)		$ (0.63)		$ (0.63)
Net loss attributable to common stockholders per common share — diluted (in dollars per share) \| $ / shares		$ (0.12)		$ (0.19)		$ (0.63)		$ (0.63)
Weighted average common shares outstanding - basic (in shares) \| shares	289,223,709		267,464,637		288,841,092		266,085,788
Weighted average common shares outstanding - diluted (in shares) \| shares	289,223,709		267,464,637		288,841,092		266,085,788

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (33,286)	$ (50,294)	$ (180,703)	$ (167,183)
Other comprehensive loss:
Foreign currency translation adjustment loss	(22,121)	(2,638)	(43,975)	(1,795)
Unrealized gain (loss) on available-for-sale securities	283	(11)	(84)	1
Other comprehensive loss	(21,838)	(2,649)	(44,059)	(1,794)
Comprehensive loss	$ (55,124)	$ (52,943)	$ (224,762)	$ (168,977)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Warrants	Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020		262,063,461
Beginning balance at Dec. 31, 2020	$ 286,380	$ 2,650	$ 2,308,578	$ 12,387	$ 8,227	$ (2,045,462)
Increase (Decrease) in Stockholders' Equity
Stock options exercised, net (in shares)		1,171,279
Stock options exercised, net	8,357	$ 12	8,345
Vesting of restricted stock units, net of taxes (in shares)		1,026,337
Vesting of restricted stock units, net of taxes	(14,700)		(14,700)
Stock-based compensation	43,931		43,931
Warrants exercised (in shares)		2,554,999
Warrants exercised	19,230	$ 26	31,591	(12,387)
Equity component of the convertible notes (in shares)		472,356
Equity component of the convertible notes	2,661	$ 5	2,656
Common stock issued from equity financing and pre-funded warrants (in shares)		11,296,660
Common stock issued from equity financing and pre-funded warrants	199,747	$ 112	199,552	83
Unrealized gain (loss) on available-for-sale securities	1				1
Foreign currency translation adjustment	(1,795)				(1,795)
Net loss	(167,183)					(167,183)
Ending balance (in shares) at Sep. 30, 2021		278,585,092
Ending balance at Sep. 30, 2021	376,629	$ 2,805	2,579,953	83	6,433	(2,212,645)
Beginning balance (in shares) at Jun. 30, 2021		266,532,536
Beginning balance at Jun. 30, 2021	213,910	$ 2,685	2,364,494	0	9,082	(2,162,351)
Increase (Decrease) in Stockholders' Equity
Stock options exercised, net (in shares)		248,617
Stock options exercised, net	1,696	$ 3	1,693
Vesting of restricted stock units, net of taxes (in shares)		39,007
Vesting of restricted stock units, net of taxes	(262)		(262)
Stock-based compensation	11,841		11,841
Equity component of the convertible notes (in shares)		468,272
Equity component of the convertible notes	2,640	$ 5	2,635
Common stock issued from equity financing and pre-funded warrants (in shares)		11,296,660
Common stock issued from equity financing and pre-funded warrants	199,747	$ 112	199,552	83
Unrealized gain (loss) on available-for-sale securities	(11)				(11)
Foreign currency translation adjustment	(2,638)				(2,638)
Net loss	(50,294)					(50,294)
Ending balance (in shares) at Sep. 30, 2021		278,585,092
Ending balance at Sep. 30, 2021	$ 376,629	$ 2,805	2,579,953	83	6,433	(2,212,645)
Beginning balance (in shares) at Dec. 31, 2021	278,912,800	278,912,800
Beginning balance at Dec. 31, 2021	$ 307,369	$ 2,808	2,595,419	83	4,981	(2,295,922)
Increase (Decrease) in Stockholders' Equity
Stock options exercised, net (in shares)	511,000	506,823
Stock options exercised, net	$ 3,191	$ 5	3,186
Vesting of restricted stock units, net of taxes (in shares)		1,467,513
Vesting of restricted stock units, net of taxes	(11,119)		(11,119)
Stock-based compensation	57,886		57,886
Unrealized gain (loss) on available-for-sale securities	(84)				(84)
Foreign currency translation adjustment	(43,975)				(43,975)
Net loss	$ (180,703)					(180,703)
Ending balance (in shares) at Sep. 30, 2022	280,887,136	280,887,136
Ending balance at Sep. 30, 2022	$ 132,565	$ 2,813	2,645,372	83	(39,078)	(2,476,625)
Beginning balance (in shares) at Jun. 30, 2022		280,456,667
Beginning balance at Jun. 30, 2022	173,425	$ 2,811	2,631,110	83	(17,240)	(2,443,339)
Increase (Decrease) in Stockholders' Equity
Stock options exercised, net (in shares)		172,118
Stock options exercised, net	1,333	$ 2	1,331
Vesting of restricted stock units, net of taxes (in shares)		258,351
Vesting of restricted stock units, net of taxes	(1,841)		(1,841)
Stock-based compensation	14,772		14,772
Unrealized gain (loss) on available-for-sale securities	283				283
Foreign currency translation adjustment	(22,121)				(22,121)
Net loss	$ (33,286)					(33,286)
Ending balance (in shares) at Sep. 30, 2022	280,887,136	280,887,136
Ending balance at Sep. 30, 2022	$ 132,565	$ 2,813	$ 2,645,372	$ 83	$ (39,078)	$ (2,476,625)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (180,703)	$ (167,183)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred financing	1,963	1,852
Depreciation and amortization	4,031	4,691
Stock-based compensation	57,886	43,931
Loss on extinguishment of debt	0	257
Non-cash changes in the fair value of contingent consideration payable	(506)	4,780
Foreign currency remeasurement loss	2,828	4,247
Asset impairment charges and other asset write-offs	17,271	0
Changes in operating assets and liabilities:
Accounts receivable	(7,426)	(6,372)
Inventories	4,913	(3,022)
Prepaid expenses and other current assets	(5,583)	9,080
Accounts payable, accrued expenses, and other current liabilities	25,465	(22,068)
Other non-current assets and liabilities	(5,942)	(2,170)
Net cash used in operating activities	(85,803)	(131,977)
Investing activities
Sale and redemption of marketable securities	259,920	342,343
Purchases of marketable securities	(99,811)	(193,369)
Capital expenditures	(1,089)	(2,124)
Net cash provided by investing activities	159,020	146,850
Financing activities
Payment of finance leases	(92)	(460)
Proceeds from warrants exercised, net	0	19,230
Purchase of vested restricted stock units, net of taxes	(11,119)	(14,700)
Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs	0	199,750
Proceeds from stock options exercised, net	3,191	8,357
Net cash (used in) provided by financing activities	(8,020)	212,177
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(33,120)	(4,141)
Net increase in cash, cash equivalents, and restricted cash at the end of the period	32,077	222,909
Cash, cash equivalents, and restricted cash at the beginning of period	249,456	166,162
Cash, cash equivalents, and restricted cash at the end of period	281,533	389,071
Supplemental disclosures of cash flow information
Cash paid during the period for interest	24,058	22,788
Cash paid for taxes	935	9,854
Capital expenditures unpaid at the end of period	53	327
Tenant improvements paid through lease incentives	$ 0	$ 67

Description of Business

Description of Business	9 Months Ended
Description of Business	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA") as well as the European Medicines Agency ("EMA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases. The cornerstone of the Company's portfolio is Galafold ® (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold ® in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (“MAA”) in the fourth quarter of 2021. On May 9, 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. In October 2022, the FDA deferred action on the BLA for cipaglucosidase alfa, citing the inability to complete the manufacturing facility inspection prior to the PDUFA action date. The Company is actively engaged with the FDA on developing an inspection plan . The Company continues to monitor the novel coronavirus (“COVID-19”) pandemic. The Company's commercial operations have not been significantly impacted by the COVID-19 pandemic to date. The Company continued to observe increased lag time between patient identification and Galafold ® initiation due to the continued prevalence of COVID-19 and its ongoing impact on access to treatment for people living with Fabry disease in certain markets. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimal disruptions. Whether the Company will continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold® and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. In regard to the Company’s regulatory operations, the FDA deferred action on the pending BLA for cipaglucosidase alfa, as a facility inspection was necessary, however, could not be completed by the PDUFA action date due to COVID-19 related travel restrictions. Per FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, receipt of a deferral action indicates no deficiencies have been identified and the application otherwise satisfies the requirements for approval. The Company had an accumulated deficit of $2.5 billion as of September 30, 2022 and anticipates incurring losses through the fiscal year ending December 31, 2022 and beyond. The Company has historically funded its operations through stock offerings, Galafold ® revenues, debt issuances, collaborations, and other financing arrangements. Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information. The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. For a complete description of the Company's accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Consolidation The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation. Foreign Currency Transactions The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Additionally, the Company assessed the impact of the COVID-19 pandemic has had on its operations and financial results as of September 30, 2022 and through the issuance of these financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Cash, Cash Equivalents, Marketable Securities, and Restricted Cash The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs. Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. Concentration of Credit Risk The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities. The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold ® . The Company's accounts receivable at September 30, 2022 have arisen from product sales primarily in Europe, the U.S. and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of September 30, 2022, the Company recorded an allowance for doubtful accounts of $0.1 million. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made. During the nine months ended September 30, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6 million. Revenue Recognition The Company's net product sales consist primarily of sales of Galafold ® for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold ® is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold ® are generally received from distributors and pharmacies, with the ultimate payor often a government authority. The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold ® . The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold ® is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. The following table summarizes the Company's net product sales disaggregated by geographic area: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 U.S. $ 30,222 $ 25,636 $ 81,940 $ 70,167 Ex-U.S. 51,469 53,909 159,197 153,193 Total net product sales $ 81,691 $ 79,545 $ 241,137 $ 223,360 Inventories and Cost of Goods Sold Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations. Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. Research and Development Costs Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. In the second quarter of 2022, as part of the Company’s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $20.0 million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. As of September 30, 2022, this liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets. Recent Accounting Developments The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.

Cash, Cash Equivalents, Marketa

Cash, Cash Equivalents, Marketable Securities, and Restricted Cash	9 Months Ended
	Sep. 30, 2022
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Cash, Cash Equivalents, Marketable Securities, and Restricted Cash	Cash, Cash Equivalents, Marketable Securities, and Restricted Cash As of September 30, 2022, the Company held $277.6 million in cash and cash equivalents and $77.1 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security’s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss, the Company would recognize an allowance and the corresponding credit loss would be included in earnings. The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current. Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: As of September 30, 2022 (in thousands) Cost Gross Gross Fair Cash and cash equivalents $ 277,592 $ — $ — $ 277,592 U.S. government agency bonds 40,042 — (87) 39,955 Commercial paper 36,821 — (69) 36,752 Money market 350 — — 350 Certificates of deposit 51 — — 51 $ 354,856 $ — $ (156) $ 354,700 Included in cash and cash equivalents $ 277,592 $ — $ — $ 277,592 Included in marketable securities 77,264 — (156) 77,108 Total cash, cash equivalents, and marketable securities $ 354,856 $ — $ (156) $ 354,700 As of December 31, 2021 (in thousands) Cost Gross Gross Fair Cash and cash equivalents $ 245,197 $ — $ — $ 245,197 Commercial paper 174,578 7 (54) 174,531 Corporate debt securities 32,322 — (11) 32,311 Asset-backed securities 30,070 — (14) 30,056 Money market 350 — — 350 Certificate of deposit 51 — — 51 $ 482,568 $ 7 $ (79) $ 482,496 Included in cash and cash equivalents $ 245,197 $ — $ — $ 245,197 Included in marketable securities 237,371 7 (79) 237,299 Total cash, cash equivalents, and marketable securities $ 482,568 $ 7 $ (79) $ 482,496 For both the nine months ended September 30, 2022 and the fiscal year ended December 31, 2021, there were no realized gains or losses. The cost of securities sold is based on the specific identification method. Unrealized loss positions in the marketable securities as of September 30, 2022 and December 31, 2021 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $76.7 million and $173.4 million as of September 30, 2022 and December 31, 2021, respectively. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows. As of September 30, (in thousands) 2022 2021 Cash and cash equivalents $ 277,592 $ 385,903 Restricted cash 3,941 3,168 Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows $ 281,533 $ 389,071

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold ® . The following table summarizes the components of inventories: (in thousands) September 30, 2022 December 31, 2021 Raw materials $ 6,075 $ 12,289 Work-in-process 2,617 10,699 Finished goods 4,580 3,830 Total inventories $ 13,272 $ 26,818

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt The Company's debt consists of the following: (in thousands) September 30, 2022 December 31, 2021 Senior Secured Term Loan due 2026: Principal $ 400,000 $ 400,000 Less: debt discount (1) (4,954) (6,074) Less: deferred financing (1) (3,727) (4,569) Net carrying value of Long-term debt $ 391,319 $ 389,357 ______________________________ (1) Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method. Interest Expense The following table sets forth interest expense recognized related to the Company's debt for the three and nine months ended September 30, 2022 and 2021, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Contractual interest expense $ 8,945 $ 7,681 $ 24,034 $ 22,806 Amortization of debt discount $ 382 $ 383 $ 1,121 $ 1,098 Amortization of deferred financing $ 286 $ 269 $ 842 $ 754

Share-Based Compensation

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based CompensationThe Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Stock Option Grants The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected stock price volatility 61.0 % 62.7 % 62.2 % 65.8 % Risk free interest rate 3.1 % 0.8 % 1.7 % 0.5 % Expected life of options (years) 5.3 5.4 5.3 5.4 Expected annual dividend per share $ — $ — $ — $ — A summary of the Company's stock options for the nine months ended September 30, 2022 were as follows: Number of Weighted Average Exercise Weighted Average Remaining Aggregate (in thousands) (in millions) Options outstanding, December 31, 2021 14,731 $ 11.08 Granted 5,644 $ 11.53 Exercised (511) $ 6.32 Forfeited (435) $ 12.59 Expired (193) $ 12.21 Options outstanding, September 30, 2022 19,236 $ 11.30 6.8 $ 18.9 Vested and unvested expected to vest, September 30, 2022 17,587 $ 11.20 6.6 $ 18.4 Exercisable at September 30, 2022 10,655 $ 10.49 5.1 $ 16.1 As of September 30, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $35.5 million and is expected to be recognized over a weighted average period of three years. Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs") RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2022 is as follows: Number of Weighted Weighted Aggregate (in thousands) (in millions) Non-vested units as of December 31, 2021 7,341 $ 13.90 Granted 4,998 $ 11.93 Vested (2,144) $ 12.50 Forfeited (356) $ 12.19 Non-vested units as of September 30, 2022 9,839 $ 13.06 2.3 $ 102.7 All non-vested units are expected to vest over their normal term. As of September 30, 2022, there was $58.2 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years. Compensation Expense Related to Equity Awards The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Research and development expense $ 5,428 $ 3,775 $ 19,172 $ 13,232 Selling, general, and administrative expense 9,344 8,066 38,714 30,699 Total equity compensation expense $ 14,772 $ 11,841 $ 57,886 $ 43,931

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value	9 Months Ended
Assets and Liabilities Measured at Fair Value	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value	Assets and Liabilities Measured at Fair Value The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. Level 3 — Inputs that are unobservable for the asset or liability. A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2022 are identified in the following tables: (in thousands) Level 2 Total Assets: U.S. government agency bonds $ 39,955 $ 39,955 Commercial paper 36,753 36,753 Money market 5,352 5,352 $ 82,060 $ 82,060 (in thousands) Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ 19,833 $ 19,833 Deferred compensation plan liability 5,002 — 5,002 $ 5,002 $ 19,833 $ 24,835 A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables: (in thousands) Level 2 Total Assets: Commercial paper $ 174,531 $ 174,531 Corporate debt securities 32,311 32,311 Asset-backed securities 30,056 30,056 Money market 5,150 5,150 $ 242,048 $ 242,048 (in thousands) Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ 20,339 $ 20,339 Deferred compensation plan liability 4,800 — 4,800 $ 4,800 $ 20,339 $ 25,139 The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value. The Company did not have any Level 3 assets as of September 30, 2022 or December 31, 2021. Cash, Money Market Funds, and Marketable Securities The Company classifies its cash within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. Contingent Consideration Payable The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: Contingent Consideration Liability Fair Value as of September 30, 2022 Valuation Technique Unobservable Input Range (in thousands) Discount rate 8.8% Clinical and regulatory milestones $ 19,833 Probability weighted discounted cash flow Probability of achievement of milestones 80% - 88% Projected year of payments 2023 Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met. The following table shows the change in the balance of contingent consideration payable for the three and nine months ended September 30, 2022 and 2021, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Balance, beginning of the period $ 19,266 $ 27,317 $ 20,339 $ 25,825 Changes in fair value during the period, included in the Consolidated Statements of Operations 567 3,288 (506) 4,780 Milestone payment payable in cash — (6,000) — (6,000) Balance, end of the period (1) $ 19,833 $ 24,605 $ 19,833 $ 24,605 ______________________________ (1) As certain milestones are expected to be reached within the next twelve months, the September 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Common Share	9 Months Ended
Basic and Diluted Net Loss per Common Share	Sep. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share amounts) 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (33,286) $ (50,294) $ (180,703) $ (167,183) Denominator: Weighted average common shares outstanding — basic and diluted 289,223,709 267,464,637 288,841,092 266,085,788 Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. Weighted average common shares outstanding includes outstanding pre-funded warrants with an exercise price of $0.01. The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method: As of September 30, (in thousands) 2022 2021 Options to purchase common stock 19,236 14,798 Unvested restricted stock units 9,839 7,540 Total number of potentially issuable shares 29,075 22,338

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.
Consolidation	Consolidation The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.
Foreign Currency Transactions	Foreign Currency Transactions The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Additionally, the Company assessed the impact of the COVID-19 pandemic has had on its operations and financial results as of September 30, 2022 and through the issuance of these financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.
Cash, Cash Equivalents, Marketable Securities and Restricted Cash	Cash, Cash Equivalents, Marketable Securities, and Restricted Cash The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive loss in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.
Concentration of Credit Risk	Concentration of Credit Risk The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities. The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold ®
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy. The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.
Revenue Recognition	Revenue Recognition The Company's net product sales consist primarily of sales of Galafold ® for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold ® is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold ® are generally received from distributors and pharmacies, with the ultimate payor often a government authority. The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold ® . The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold ® is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.
Inventories and Cost of Goods Sold	Inventories and Cost of Goods Sold Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development. In the second quarter of 2022, as part of the Company’s strategic prioritization of its gene therapy portfolio, the Company recorded a non-recurring $20.0 million liability associated with the expense of contractual obligations from which the Company will no longer receive further economic benefit. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity is recognized at the cease-use date. As of September 30, 2022, this liability is presented as a component of accrued expenses and other current liabilities within the Company's Consolidated Balance Sheets.
Recent Accounting Developments	Recent Accounting Developments The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2022
Accounting Policies [Abstract]
Disaggregation of Revenue	The following table summarizes the Company's net product sales disaggregated by geographic area: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 U.S. $ 30,222 $ 25,636 $ 81,940 $ 70,167 Ex-U.S. 51,469 53,909 159,197 153,193 Total net product sales $ 81,691 $ 79,545 $ 241,137 $ 223,360

Cash, Cash Equivalents, Marke_2

Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)	9 Months Ended
	Sep. 30, 2022
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Schedule of Cash, Cash Equivalents and Marketable Securities	Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: As of September 30, 2022 (in thousands) Cost Gross Gross Fair Cash and cash equivalents $ 277,592 $ — $ — $ 277,592 U.S. government agency bonds 40,042 — (87) 39,955 Commercial paper 36,821 — (69) 36,752 Money market 350 — — 350 Certificates of deposit 51 — — 51 $ 354,856 $ — $ (156) $ 354,700 Included in cash and cash equivalents $ 277,592 $ — $ — $ 277,592 Included in marketable securities 77,264 — (156) 77,108 Total cash, cash equivalents, and marketable securities $ 354,856 $ — $ (156) $ 354,700 As of December 31, 2021 (in thousands) Cost Gross Gross Fair Cash and cash equivalents $ 245,197 $ — $ — $ 245,197 Commercial paper 174,578 7 (54) 174,531 Corporate debt securities 32,322 — (11) 32,311 Asset-backed securities 30,070 — (14) 30,056 Money market 350 — — 350 Certificate of deposit 51 — — 51 $ 482,568 $ 7 $ (79) $ 482,496 Included in cash and cash equivalents $ 245,197 $ — $ — $ 245,197 Included in marketable securities 237,371 7 (79) 237,299 Total cash, cash equivalents, and marketable securities $ 482,568 $ 7 $ (79) $ 482,496
Schedule of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows. As of September 30, (in thousands) 2022 2021 Cash and cash equivalents $ 277,592 $ 385,903 Restricted cash 3,941 3,168 Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows $ 281,533 $ 389,071

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories for the Period	The following table summarizes the components of inventories: (in thousands) September 30, 2022 December 31, 2021 Raw materials $ 6,075 $ 12,289 Work-in-process 2,617 10,699 Finished goods 4,580 3,830 Total inventories $ 13,272 $ 26,818

Debt (Tables)

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Liability Components of Long-Term Debt	The Company's debt consists of the following: (in thousands) September 30, 2022 December 31, 2021 Senior Secured Term Loan due 2026: Principal $ 400,000 $ 400,000 Less: debt discount (1) (4,954) (6,074) Less: deferred financing (1) (3,727) (4,569) Net carrying value of Long-term debt $ 391,319 $ 389,357 ______________________________ (1) Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan due 2026 using the effective interest rate method.
Schedule of Components of Total Interest Expense	The following table sets forth interest expense recognized related to the Company's debt for the three and nine months ended September 30, 2022 and 2021, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Contractual interest expense $ 8,945 $ 7,681 $ 24,034 $ 22,806 Amortization of debt discount $ 382 $ 383 $ 1,121 $ 1,098 Amortization of deferred financing $ 286 $ 269 $ 842 $ 754

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
Share-Based Compensation (Tables)	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Fair Value of Options	The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected stock price volatility 61.0 % 62.7 % 62.2 % 65.8 % Risk free interest rate 3.1 % 0.8 % 1.7 % 0.5 % Expected life of options (years) 5.3 5.4 5.3 5.4 Expected annual dividend per share $ — $ — $ — $ —
Schedule of Stock Options Activity	A summary of the Company's stock options for the nine months ended September 30, 2022 were as follows: Number of Weighted Average Exercise Weighted Average Remaining Aggregate (in thousands) (in millions) Options outstanding, December 31, 2021 14,731 $ 11.08 Granted 5,644 $ 11.53 Exercised (511) $ 6.32 Forfeited (435) $ 12.59 Expired (193) $ 12.21 Options outstanding, September 30, 2022 19,236 $ 11.30 6.8 $ 18.9 Vested and unvested expected to vest, September 30, 2022 17,587 $ 11.20 6.6 $ 18.4 Exercisable at September 30, 2022 10,655 $ 10.49 5.1 $ 16.1
Schedule of Non-Vested RSU Activity under the Plan	A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2022 is as follows: Number of Weighted Weighted Aggregate (in thousands) (in millions) Non-vested units as of December 31, 2021 7,341 $ 13.90 Granted 4,998 $ 11.93 Vested (2,144) $ 12.50 Forfeited (356) $ 12.19 Non-vested units as of September 30, 2022 9,839 $ 13.06 2.3 $ 102.7
Schedule of Equity Compensation Expenses	The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Research and development expense $ 5,428 $ 3,775 $ 19,172 $ 13,232 Selling, general, and administrative expense 9,344 8,066 38,714 30,699 Total equity compensation expense $ 14,772 $ 11,841 $ 57,886 $ 43,931

Assets and Liabilities Measur_2

Assets and Liabilities Measured at Fair Value (Tables)	9 Months Ended
Assets and Liabilities Measured at Fair Value (Tables)	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Subject to Fair Value Measurements	A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2022 are identified in the following tables: (in thousands) Level 2 Total Assets: U.S. government agency bonds $ 39,955 $ 39,955 Commercial paper 36,753 36,753 Money market 5,352 5,352 $ 82,060 $ 82,060 (in thousands) Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ 19,833 $ 19,833 Deferred compensation plan liability 5,002 — 5,002 $ 5,002 $ 19,833 $ 24,835 A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables: (in thousands) Level 2 Total Assets: Commercial paper $ 174,531 $ 174,531 Corporate debt securities 32,311 32,311 Asset-backed securities 30,056 30,056 Money market 5,150 5,150 $ 242,048 $ 242,048 (in thousands) Level 2 Level 3 Total Liabilities: Contingent consideration payable $ — $ 20,339 $ 20,339 Deferred compensation plan liability 4,800 — 4,800 $ 4,800 $ 20,339 $ 25,139
Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable	The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program: Contingent Consideration Liability Fair Value as of September 30, 2022 Valuation Technique Unobservable Input Range (in thousands) Discount rate 8.8% Clinical and regulatory milestones $ 19,833 Probability weighted discounted cash flow Probability of achievement of milestones 80% - 88% Projected year of payments 2023
Schedule of Changes in Continent Consideration Payable	The following table shows the change in the balance of contingent consideration payable for the three and nine months ended September 30, 2022 and 2021, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Balance, beginning of the period $ 19,266 $ 27,317 $ 20,339 $ 25,825 Changes in fair value during the period, included in the Consolidated Statements of Operations 567 3,288 (506) 4,780 Milestone payment payable in cash — (6,000) — (6,000) Balance, end of the period (1) $ 19,833 $ 24,605 $ 19,833 $ 24,605 ______________________________ (1) As certain milestones are expected to be reached within the next twelve months, the September 30, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Common Share (Tables)	9 Months Ended
Basic and Diluted Net Loss per Common Share (Tables)	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Common Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share amounts) 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (33,286) $ (50,294) $ (180,703) $ (167,183) Denominator: Weighted average common shares outstanding — basic and diluted 289,223,709 267,464,637 288,841,092 266,085,788
Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method	The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method: As of September 30, (in thousands) 2022 2021 Options to purchase common stock 19,236 14,798 Unvested restricted stock units 9,839 7,540 Total number of potentially issuable shares 29,075 22,338

Description of Business (Detail

Description of Business (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 2,476,625	$ 2,295,922

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Allowance for doubtful accounts receivable	$ 100		$ 100
Loss on impairment of assets	0	$ 0	6,616	$ 0
Net product sales	81,691	79,545	241,137	223,360
Contractual obligation					$ 20,000
U.S.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net product sales	30,222	25,636	81,940	70,167
Ex-U.S.
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net product sales	$ 51,469	$ 53,909	$ 159,197	$ 153,193
Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful life			3 years
Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful life			5 years

Cash, Cash Equivalents, Marke_3

Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Cash, Money Market Funds, and Marketable Securities
Cash and cash equivalents	$ 277,592,000	$ 245,197,000	$ 385,903,000
Available-for-sale debt securities	77,108,000	237,299,000
Realized gain (loss) on debt securities	0	0
Fair value of available-for-sale debt securities in unrealized loss positions	76,700,000	$ 173,400,000
Marketable Securities
Cash, Money Market Funds, and Marketable Securities
Available-for-sale debt securities	$ 77,100,000

Cash, Cash Equivalents, Marke_4

Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Cash, Money Market Funds, and Marketable Securities
Cash and cash equivalents	$ 277,592	$ 245,197	$ 385,903
Fair value, cash balances	277,592	245,197
Cost, available-for-sale securities	77,264	237,371
Gross unrealized gain, available-for-sale securities	0	7
Gross unrealized loss, available-for-sale securities	(156)	(79)
Fair value, available-for-sale debt securities	77,108	237,299
Cost, cash balances and available-for-sale securities	354,856	482,568
Gross unrealized gain, cash balances and available-for-sale securities	0	7
Gross unrealized loss, cash balances and available-for-sale securities	(156)	(79)
Fair value, cash balances and available-for-sale securities	354,700	482,496
U.S. government agency bonds
Cash, Money Market Funds, and Marketable Securities
Corporate debt securities, cost	40,042
Corporate debt securities, gross unrealized gain	0
Corporate debt securities, gross unrealized loss	(87)
Corporate debt securities, fair value	39,955
Commercial paper
Cash, Money Market Funds, and Marketable Securities
Cost, available-for-sale securities	36,821	174,578
Gross unrealized gain, available-for-sale securities	0	7
Gross unrealized loss, available-for-sale securities	(69)	(54)
Fair value, available-for-sale debt securities	36,752	174,531
Corporate debt securities
Cash, Money Market Funds, and Marketable Securities
Corporate debt securities, cost		32,322
Corporate debt securities, gross unrealized gain		0
Corporate debt securities, gross unrealized loss		(11)
Corporate debt securities, fair value		32,311
Asset-backed securities
Cash, Money Market Funds, and Marketable Securities
Corporate debt securities, cost		30,070
Corporate debt securities, gross unrealized gain		0
Corporate debt securities, gross unrealized loss		(14)
Corporate debt securities, fair value		30,056
Money market
Cash, Money Market Funds, and Marketable Securities
Corporate debt securities, cost	350
Corporate debt securities, gross unrealized gain	0
Corporate debt securities, gross unrealized loss	0
Corporate debt securities, fair value	350
Cost, available-for-sale securities		350
Gross unrealized gain, available-for-sale securities		0
Gross unrealized loss, available-for-sale securities		0
Fair value, available-for-sale debt securities		350
Certificate of deposit
Cash, Money Market Funds, and Marketable Securities
Cost, available-for-sale securities	51	51
Gross unrealized gain, available-for-sale securities	0	0
Gross unrealized loss, available-for-sale securities	0	0
Fair value, available-for-sale debt securities	$ 51	$ 51

Cash, Cash Equivalents, Marke_5

Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Cash, Cash Equivalents, and Short-Term Investments [Abstract]
Cash and cash equivalents	$ 277,592	$ 245,197	$ 385,903
Restricted cash	3,941		3,168
Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows	$ 281,533	$ 249,456	$ 389,071	$ 166,162

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 6,075	$ 12,289
Work-in-process	2,617	10,699
Finished goods	4,580	3,830
Total inventories	$ 13,272	$ 26,818

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Reserve for inventory	$ 0.2	$ 1.1

Debt - Summary of Long Term Deb

Debt - Summary of Long Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Net carrying value of Long-term debt	$ 391,319	$ 389,357
Senior Loans \| Senior Secured Term Loan due 2026
Debt Instrument [Line Items]
Principal	400,000	400,000
Less: debt discount	(4,954)	(6,074)
Less: deferred financing	$ (3,727)	$ (4,569)

Debt - Interest Expense (Detail

Debt - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Debt - Interest Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Contractual interest expense	$ 8,945	$ 7,681	$ 24,034	$ 22,806
Amortization of debt discount	382	383	1,121	1,098
Amortization of deferred financing	$ 286	$ 269	$ 842	$ 754

Share-Based Compensation - Weig

Share-Based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	61%	62.70%	62.20%	65.80%
Risk free interest rate	3.10%	0.80%	1.70%	0.50%
Expected life of options (years)	5 years 3 months 18 days	5 years 4 months 24 days	5 years 3 months 18 days	5 years 4 months 24 days
Expected annual dividend per share (in dollars per share)	$ 0	$ 0	$ 0	$ 0

Share-Based Compensation - Stoc

Share-Based Compensation - Stock Option Activity (Details) shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2022 $ / shares shares	Sep. 30, 2022 USD ($) shares
Number of Shares
Options outstanding (in shares) \| shares	14,731
Options, granted (in shares) \| shares	5,644
Options, exercised (in shares) \| shares	(511)
Options, forfeited (in shares) \| shares	(435)
Options, expired (in shares) \| shares	(193)
Options outstanding (in shares) \| shares	19,236
Options, vested and unvested expected to vest (in shares) \| shares		17,587
Options, exercisable (in shares) \| shares		10,655
Weighted Average Exercise Price
Options outstanding (in dollars per share) \| $ / shares	$ 11.08
Options, granted (in dollars per share) \| $ / shares	11.53
Options, exercised (in dollars per share) \| $ / shares	6.32
Options, forfeited (in dollars per share) \| $ / shares	12.59
Options, expired (in dollars per share) \| $ / shares	12.21
Options outstanding (in dollars per share) \| $ / shares	11.30
Options, vested and unvested expected to vest (in dollars per share) \| $ / shares	11.20
Options, exercisable (in dollars per share) \| $ / shares	$ 10.49
Additional Disclosures
Weighted average remaining contractual life, options outstanding	6 years 9 months 18 days
Weighted average remaining contractual life, options vested and unvested expected to vest	6 years 7 months 6 days
Weighted average remaining contractual life, options exercisable	5 years 1 month 6 days
Aggregate intrinsic value, options outstanding \| $		$ 18.9
Aggregate intrinsic value, vested and unvested expected to vest \| $		18.4
Aggregate intrinsic value, exercisable \| $		$ 16.1

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs	$ 35.5
Unrecognized compensation costs, period for recognition (in years)	3 years
Unvested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs	$ 58.2
Unrecognized compensation costs, period for recognition (in years)	2 years

Share-Based Compensation - RSUs

Share-Based Compensation - RSUs and PBRSUs Summary (Details) - Unvested restricted stock units shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Number of Shares
Non-vested units (in shares) \| shares	7,341
Granted (in shares) \| shares	4,998
Vested (in shares) \| shares	(2,144)
Forfeited (in shares) \| shares	(356)
Non-vested units (in shares) \| shares	9,839
Weighted Average Grant Date Fair Value
Non-vested units (in dollars per share) \| $ / shares	$ 13.90
Granted (in dollars per share) \| $ / shares	11.93
Vested (in dollars per share) \| $ / shares	12.50
Forfeited (in dollars per share) \| $ / shares	12.19
Non-vested units (in dollars per share) \| $ / shares	$ 13.06
Additional Disclosures
Non-vested units, weighted average remaining years	2 years 3 months 18 days
Non-vested units, aggregate intrinsic value \| $	$ 102.7

Share-Based Compensation - Expe

Share-Based Compensation - Expense Summary (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total equity compensation expense	$ 14,772	$ 11,841	$ 57,886	$ 43,931
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total equity compensation expense	5,428	3,775	19,172	13,232
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total equity compensation expense	$ 9,344	$ 8,066	$ 38,714	$ 30,699

Assets and Liabilities Measur_3

Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets:
Fair value of assets	$ 82,060	$ 242,048
Liabilities:
Contingent consideration payable	19,833	20,339
Deferred compensation plan liability	5,002	4,800
Fair value of liabilities	24,835	25,139
U.S. government agency bonds
Assets:
Fair value of assets	39,955
Commercial paper
Assets:
Fair value of assets	36,753	174,531
Asset-backed securities
Assets:
Fair value of assets		30,056
Money market
Assets:
Fair value of assets	5,352	5,150
Level 2
Assets:
Fair value of assets	82,060	242,048
Liabilities:
Contingent consideration payable	0	0
Deferred compensation plan liability	5,002	4,800
Fair value of liabilities	5,002	4,800
Level 2 \| U.S. government agency bonds
Assets:
Fair value of assets	39,955
Level 2 \| Commercial paper
Assets:
Fair value of assets	36,753
Level 2 \| Corporate debt securities
Assets:
Fair value of assets		32,311
Level 2 \| Asset-backed securities
Assets:
Fair value of assets		30,056
Level 2 \| Money market
Assets:
Fair value of assets	5,352	5,150
Level 3
Liabilities:
Contingent consideration payable	19,833	20,339
Deferred compensation plan liability	0	0
Fair value of liabilities	$ 19,833	$ 20,339

Assets and Liabilities Measur_4

Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration payable	$ 19,833	$ 20,339
Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration payable	19,833	$ 20,339
Callidus Biopharma Inc \| Clinical and regulatory milestones \| ATB200 Pompe Program
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration payable	$ 19,833
Callidus Biopharma Inc \| Clinical and regulatory milestones \| Probability of achievement of milestones \| ATB200 Pompe Program \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, measurement input	80%
Callidus Biopharma Inc \| Clinical and regulatory milestones \| Probability of achievement of milestones \| ATB200 Pompe Program \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, measurement input	88%
Callidus Biopharma Inc \| Clinical and regulatory milestones \| Discount rate \| Discount rate \| ATB200 Pompe Program \| Probability weighted discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, measurement input	8.80%

Assets and Liabilities Measur_5

Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of the period	$ 19,266	$ 27,317	$ 20,339	$ 25,825
Changes in fair value during the period, included in the Consolidated Statements of Operations	567	3,288	(506)	4,780
Milestone payment payable in cash	0	(6,000)	0	(6,000)
Balance, end of the period	$ 19,833	$ 24,605	$ 19,833	$ 24,605

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Common Share (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Sep. 30, 2022 $ / shares
Numerator:
Net loss attributable to common stockholders \| $	$ (33,286)	$ (50,294)	$ (180,703)	$ (167,183)
Denominator:
Weighted average common shares outstanding - basic (in shares)	289,223,709	267,464,637	288,841,092	266,085,788
Weighted average common shares outstanding - diluted (in shares)	289,223,709	267,464,637	288,841,092	266,085,788
Antidilutive securities excluded from computation of diluted earnings per share (in shares)			29,075,000	22,338,000
Options to purchase common stock
Denominator:
Antidilutive securities excluded from computation of diluted earnings per share (in shares)			19,236,000	14,798,000
Unvested restricted stock units
Denominator:
Antidilutive securities excluded from computation of diluted earnings per share (in shares)			9,839,000	7,540,000
Private Placement
Denominator:
Warrants exercise price (in dollars per share) \| $ / shares					$ 0.01